The field of radiotheranostics, which combines diagnostic imaging and targeted radiotherapy, has seen significant advancements with several promising agents being explored for precision oncology.
Lutetium-177-PSMA-617 is being used for metastatic castration-resistant prostate cancer, showcasing the potential of targeted therapy against prostate-specific membrane antigen (PSMA) to manage advanced stages of the disease.
Yttrium-90-labelled ibritumomab tiuxetan and Iodine-131 tositumomab (Bexxar) are examples of radioimmunotherapy approaches for non-Hodgkin’s lymphoma, leveraging the targeting capability of antibodies conjugated with radioactive isotopes to deliver cytotoxic radiation directly to tumour cells.
Radium-223 represents a breakthrough for treating metastatic prostate cancer, specifically targeting bone metastases and improving survival rates.
These advancements highlight the growing role of radiotheranostics in oncology, offering more precise and personalised treatment options for cancer patients. The integration of these targeted therapies into clinical practice is not only changing the landscape of cancer treatment but also reinforcing the importance of precision medicine in oncology.
#radiotheranostics
#cancertreatment
Postdoctoral Scientist
6moI also have the same thought .spheroid are organoid are different